Labgenomics Co

Labgenomics Co Pre-Tax Margin

The Pre-Tax Profit Margin of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -68.35 %. In the previous year, Pre-Tax Profit Margin was -30.21 % — a change of 126.24% (lower).

Pre-Tax Margin

-68.35 %

YoY

126.24%

Last updated:

Pre-Tax Profit Margin of Labgenomics Co is 2025 -68.35 % . Pre-Tax Profit Margin of Labgenomics Co was 2024 -30.21 % . It decreases by 126.24% lower compared to the previous year.

The Labgenomics Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-12.24 KRW
Jan 1, 2019
3.24 KRW
Jan 1, 2020
43.37 KRW
Jan 1, 2021
53.92 KRW
Jan 1, 2022
43.79 KRW
Jan 1, 2023
-10.04 KRW
Jan 1, 2024
-30.21 KRW
Jan 1, 2025
-68.35 KRW
The Labgenomics Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
-68.35 %+126.24%
-30.21 %+201.06%
-10.04 %-122.92%
43.79 %-18.79%
53.92 %+24.31%
43.37 %+1,238.20%
3.24 %-126.48%
-12.24 %-29.44%
-17.35 %-3,102.84%
0.58 %-88.39%
4.97 %-52.68%
10.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Pre-Tax Profit Margin of Labgenomics Co is -68.35 % in 2025.

Pre-Tax Profit Margin of Labgenomics Co changed from -30.21 % to -68.35 %, representing a 126.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Labgenomics Co

All Key Metrics — Labgenomics Co